@Article{crph1136,
AUTHOR = {Adak, Sourav},
TITLE = {Impacts of Drug Shortages in the Pharmaceutical Supply Chain},
JOURNAL = {Current Research in Public Health},
VOLUME = {3},
YEAR = {2024},
NUMBER = {1},
PAGES = {22-26},
URL = {https://www.scipublications.com/journal/index.php/UJPP/article/view/1136},
ISSN = {2831-5162},
DOI = {10.31586/ujpp.2024.1136},
ABSTRACT = {Drug shortages represent a significant and growing challenge within the pharmaceutical supply chain, with profound implications for patient care, public health, and healthcare costs. This manuscript provides a comprehensive examination of the causes and impacts of drug shortages, highlighting the multifaceted nature of this issue. Key factors contributing to shortages include manufacturing complications, limited availability of active pharmaceutical ingredients (APIs), market dynamics that discourage the production of less profitable medications, and regulatory challenges that slow down the approval process for new manufacturing capacities. The consequences of these shortages are far-reaching. Patients often face treatment delays, which can lead to adverse health outcomes, increased hospitalization rates, and even mortality. Healthcare providers experience heightened operational costs as they seek alternative therapies and manage complications resulting from inadequate treatment. Furthermore, the frequent occurrence of drug shortages erodes public trust in both the healthcare system and the pharmaceutical industry, leading to decreased patient adherence to prescribed therapies. To mitigate the impacts of drug shortages, this manuscript proposes several strategic solutions, including enhanced communication among stakeholders, diversification of supply sources, increased regulatory flexibility, and collaborative approaches between public and private sectors. Additionally, raising awareness among healthcare providers and patients regarding the causes and potential alternatives can empower stakeholders to navigate shortages effectively. Ultimately, addressing drug shortages necessitates a proactive and coordinated effort from all participants in the pharmaceutical supply chain. By implementing these strategies, stakeholders can enhance the resilience of the supply chain, ensuring that essential medications remain accessible and that patient care is not compromised. The findings of this manuscript underscore the urgent need for ongoing vigilance and collaborative action to tackle the challenges posed by drug shortages, safeguarding public health and improving healthcare outcomes globally.},
}

%0 Journal Article
%A Adak, Sourav
%D 2024
%J Current Research in Public Health

%@ 2831-5162
%V 3
%N 1
%P 22-26

%T Impacts of Drug Shortages in the Pharmaceutical Supply Chain
%M doi:10.31586/ujpp.2024.1136
%U https://www.scipublications.com/journal/index.php/UJPP/article/view/1136

TY  - JOUR
AU  - Adak, Sourav
TI  - Impacts of Drug Shortages in the Pharmaceutical Supply Chain
T2  - Current Research in Public Health
PY  - 2024
VL  - 3
IS  - 1
SN  - 2831-5162
SP  - 22
EP  - 26
UR  - https://www.scipublications.com/journal/index.php/UJPP/article/view/1136
AB  - Drug shortages represent a significant and growing challenge within the pharmaceutical supply chain, with profound implications for patient care, public health, and healthcare costs. This manuscript provides a comprehensive examination of the causes and impacts of drug shortages, highlighting the multifaceted nature of this issue. Key factors contributing to shortages include manufacturing complications, limited availability of active pharmaceutical ingredients (APIs), market dynamics that discourage the production of less profitable medications, and regulatory challenges that slow down the approval process for new manufacturing capacities. The consequences of these shortages are far-reaching. Patients often face treatment delays, which can lead to adverse health outcomes, increased hospitalization rates, and even mortality. Healthcare providers experience heightened operational costs as they seek alternative therapies and manage complications resulting from inadequate treatment. Furthermore, the frequent occurrence of drug shortages erodes public trust in both the healthcare system and the pharmaceutical industry, leading to decreased patient adherence to prescribed therapies. To mitigate the impacts of drug shortages, this manuscript proposes several strategic solutions, including enhanced communication among stakeholders, diversification of supply sources, increased regulatory flexibility, and collaborative approaches between public and private sectors. Additionally, raising awareness among healthcare providers and patients regarding the causes and potential alternatives can empower stakeholders to navigate shortages effectively. Ultimately, addressing drug shortages necessitates a proactive and coordinated effort from all participants in the pharmaceutical supply chain. By implementing these strategies, stakeholders can enhance the resilience of the supply chain, ensuring that essential medications remain accessible and that patient care is not compromised. The findings of this manuscript underscore the urgent need for ongoing vigilance and collaborative action to tackle the challenges posed by drug shortages, safeguarding public health and improving healthcare outcomes globally.
DO  - Impacts of Drug Shortages in the Pharmaceutical Supply Chain
TI  - 10.31586/ujpp.2024.1136
ER  -